• Investors may be wondering whether Axogen at US$42.52 still makes sense after such a strong run, or if the current price is getting ahead of itself.
• The stock has pulled back about 4.6% over the past week, after rising 4.0% over 30 days, 37.2% year to date, 314.8% over 1 year and 373.5% over 3 years, with a 96.8% return across 5 years.
• Recent coverage has focused on Axogen's share price performance and how the stock's sharp moves compare with broader medical equipment peers. This has put questions about sustainability and risk firmly in the spotlight. At the same time, ongoing discussion around the company's position in nerve repair solutions has kept investor attention on where fair value might sit.
• Despite this track record, Axogen currently scores just 0 out of 6 on Simply Wall St's valuation checks. The rest of this article will walk through standard valuation methods for the stock and then finish with a broader framework that can help you interpret those numbers in a more complete way.

Axogen scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Axogen Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow, or DCF, model estimates what Axogen stock could be worth today by projecting future cash flows and discounting them back to a present value. It focuses on the cash the company may generate for shareholders over time rather than short term earnings swings.

For Axogen, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model. The company’s last twelve month free cash flow is about $6.2 million. Based on analyst inputs and further extrapolation by Simply Wall St, projected free cash flow reaches $7.85 million in 2026 and $48.30 million in 2028, with additional projections out to 2035.

Discounting these future cash flows back to today produces an estimated intrinsic value of about $31.86 per share. Against the current Axogen share price of $42.52, the DCF output suggests the stock is around 33.5% above this model’s fair value estimate, which screens as overvalued on this basis alone.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Axogen may be overvalued by 33.5%. Discover 44 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Axogen Price vs Sales

For companies like Axogen that are not currently profitable on an earnings basis, revenue based metrics are often more useful. The preferred metric here is the P/S ratio, which helps you see how much investors are paying for each dollar of sales, without being distorted by short term swings in earnings.

In general, the P/S investors are comfortable paying depends on expectations for future growth, the stability of those revenues and the perceived risk. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually argues for a lower one.

Axogen trades on a P/S of 9.50x, compared with an industry average of 2.68x for Medical Equipment and a peer average of 8.59x. Simply Wall St also provides a proprietary “Fair Ratio” of 4.61x, which estimates an appropriate P/S after accounting for factors such as Axogen’s earnings growth profile, profit margins, industry, market cap and company specific risks.

This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for those company specific features rather than assuming all medical equipment stocks deserve the same multiple. With Axogen’s current 9.50x P/S sitting well above the 4.61x Fair Ratio, the stock screens as overvalued on this measure.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Axogen Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a simple story for Axogen that links your view of its business to a financial forecast and a fair value. This lets you set assumptions for future revenue, earnings and margins, compare that fair value to the current price to decide if Axogen looks attractive or expensive, see different investor perspectives side by side such as a bullish view that lines up with the US$50.78 fair value and higher 2029 earnings versus a cautious view that uses the lower earnings expectations from the same analyst set, and then have your chosen Narrative update automatically as new news, guidance or earnings arrive, all within the Community page used by millions of investors.

Do you think there's more to the story for Axogen? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.